Effect of imiquimod in anogenital warts from HIV-positive men.
J Clin Virol
; 39(3): 210-4, 2007 Jul.
Article
em En
| MEDLINE
| ID: mdl-17513167
ABSTRACT
BACKGROUND:
HIV-positive patients have unpredictable local immune responses even with severe systemic immunosuppression and data reported to date is insufficient to predict the effect of imiquimod in HIV-positive patients.OBJECTIVE:
To evaluate the efficacy of 5% topical imiquimod in HIV-positive male patients with anogenital warts (AGW) and to elucidate its effect on recurrence. STUDYDESIGN:
Open-label clinical trial.RESULTS:
Of the 43 patients enrolled, 86% completed treatment. Patients' mean age was 34 years (range 19-50). Thirty-one patients were receiving highly active antiretroviral therapy (HAART) therapy. At week 16, 10 patients completely cleared lesions and 21 patients had a wart size reduction > or =50%. At 20 weeks of therapy, 17 patients achieved total clearance whereas 14 patients had a >50% wart reduction. Clearance was not influenced by CD4-counts, HIV-viral load, previous therapy, or wart localization. Of the patients who experienced a complete clearance, five (29%) had a recurrence. Mean time of recurrence was 14.4 weeks. Erythema, pruritus, and burning sensation were the most frequent local skin reactions.CONCLUSIONS:
Topical 5% imiquimod is safe and may benefit HIV-positive patients with anogenital warts particularly when it is used for up to 20 weeks. It is also useful to decrease wart recurrence.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doenças do Ânus
/
Condiloma Acuminado
/
Infecções por HIV
/
Adjuvantes Imunológicos
/
Indutores de Interferon
/
Doenças dos Genitais Masculinos
/
Aminoquinolinas
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article